Citation Impact
20 standout
Citing Papers
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Sandra Rutzner being referenced
A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).
2020
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy
2020
Author Peers
| Author | Oncology | PRM | Surgery | Immunology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Sandra Rutzner | 103 | 42 | 27 | 33 | 19 | 152 | |
| Zachary Leader | 13 | 88 | |||||
| Donal Carbaugh | 2 | 4 | 46 | 1.9k | |||
| Ruihong Wu | 14 | 30 | 297 | ||||
| G Bringmann | 6 | 37 | 380 | ||||
| Sidney H. Ingerman | 4 | 1.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...